Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

"Sure, Jim. I’ll try to answer the question. But as with everything, it’s never really black and white. You look at a number of different factors, so it’s really a multifactorial analysis to determine what the best path forward is, especially when you have so many different portfolio items or so many different drug candidates within your portfolio, right? So as I said in my prepared statements, that over the past five months, we’ve looked at and talked to a number of folks, and rather than get into the details of those discussions, which are confidential, I could say that we’ve become more optimistic about the AIM2CERV study and we believe that the portfolio that we are now moving forward with gives the company the best chance of success to demonstrate how effective our Lm-based drug candidates are, right? So it’s important to remember, we’ve had clinical trial success in the past."